Shane Schaffer, Chairman & CEO of Cingulate CING, was recently a guest on Benzinga’s All-Access.
Cingulate is a clinical-stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety associated disorders.
The company has a patented technology dubbed PTR that underpins three drug candidates currently advancing through the development pipeline - CTx1301, CTx1302, and CTx1303.
Watch the full interview here:
Featured photo by Christina Victoria Craft on Unsplash
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
